Researchers are continually testing new treatments for MDS. Many of these studies originate at Memorial Sloan Kettering. The clinical trial process is designed to advance the current standard of care for MDS.
Our doctors have led many of the clinical trials for drugs that are now considered part of standard care for MDS. In this same way, we hope to develop better treatments for MDS in the future.
As with all cancer treatment at Memorial Sloan Kettering, clinical trials involve a team approach. Doctors, scientists, and pathologists work together to care for each person with MDS. We are experts at determining who will have the most benefit from which trial.
We routinely conduct a detailed genetic analysis on the bone marrow samples from all people who are newly diagnosed with MDS. This helps us fine-tune your prognosis and identify personalized treatments that are tailored to your disease. For example, if you have a mutation in one of the so-called splicing genes, such as SF3B1 or SRSF2, you may be a candidate for our ongoing clinical trial of a novel splicing-modulator drug called H3B-8800. It was developed in part by scientists at MSK.
Here you can find a continually updated listing of Memorial Sloan Kettering’s current clinical trials for MDS.
